国际标准期刊号: 2376-127X

妊娠与儿童健康杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 学术钥匙
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Triaging Hospitalization in Threatened Preterm Labor Patients Using a Biochemical Marker and Transvaginal Ultrasound-A Pilot Implementation Study in a Tertiary Center of North India

Meenoo S, Reva Tripathi, Shakun Tyagi, Siddarth Ramji, Sarita Shah and YM Mala

Background: Hospitalization rates for threatened or arrested preterm labour pains are high but often unnecessary. The main aim of this study was to determine the need for hospitalization in patients with threatened Preterm Labor (PTL) after testing for the presence of Phosphorylated Insulin like Growth Factor Binding Protein-1 (phIGFBP-1) in cervicovaginal secretions followed by cervical length assessment.
Methods: A prospective study was conducted in a cohort of one hundred patients of threatened PTL. They were evaluated for presence of phIGFBP-1 in cervicovaginal secretions using a bedside kit followed by cervical length measurement by Transvaginal Sonography (TVS). If either phIGFBP-1 test was positive and/or cervical length was less than or equal to 25 mm, the patient was admitted and hospital protocol was followed. If phIGFBP-1 was negative and cervical length was more than 25 mm, then the patient was counselled for home management. All patients were followed till delivery.
Result: Implementation of these tests resulted in hospitalization rate of 16% in patients with threatened PTL which was a reduction by 80% and was statistically significant with p value of <0.001. No patient assigned to home management (n=84) delivered either within 48 h or 7 days of testing. Nine patients (10.7%) delivered between one to four weeks whereas the remaining 75 patients (89.2%) delivered after four weeks. Approximate cost savings varied from INR 1,62,000 to INR 1,536,570 ($2323 to $22030) for 100 patients.
Conclusion: The use of these tests will decrease burden of hospitalization amongst patients thereby resulting in minimising unnecessary treatment and medical expenses.